Hims & Hers Health (NYSE:HIMS) Stock Price Up 5.2% - What's Next?

Key Points

• Hims & Hers shares rose 5.2% to about $30.20 in mid-day trading, though volume was 92% below the stock’s average daily volume.
• The company faces ongoing legal and regulatory risks tied to allegations involving privacy and billing disclosures. Investors have until November 2, 2026, to seek lead-plaintiff status in the related class action.
• Analyst sentiment remains cautious, with an overall “Hold” rating and an average price target of $32.43. Although revenue increased 38.2% year over year to $753.2 million, the company missed quarterly EPS expectations and remains unprofitable.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares rose 5.2% during mid-day trading on Wednesday. The company traded as high as $30.23 and last traded at $30.1970. 1,836,144 shares traded hands during trading, a decline of 92% from the average daily volume of 23,752,195 shares. The stock had previously closed at $28.70.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Multiple law firms issued substantially similar notices reminding investors who acquired HIMS securities between August 4, 2025, and July 29, 2026, that November 2, 2026, is the deadline to seek appointment as lead plaintiff. The repeated announcements largely amplify the same existing lawsuit rather than identify separate new legal actions. Kaplan Fox class action notice
• Negative Sentiment: The litigation creates potential financial, reputational and compliance risks for HIMS. Plaintiffs allege that the company made material misstatements or omissions about its privacy and billing practices, while the FTC’s complaint has already been associated with a reported stock decline of more than 14%. Investors may remain concerned about possible damages, legal expenses, regulatory remedies and disruption to the company’s operations. Hagens Berman class action announcement

Analyst Ratings Changes

Several analysts recently weighed in on HIMS shares. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Hims & Hers Health in a research note on Friday, August 7th. JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They set a "neutral" rating and a $32.00 target price on the stock. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Monday, July 13th. Barclays lowered their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a research report on Friday, August 21st. Finally, Truist Financial increased their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $32.43.

Hims & Hers Health Stock Performance

The firm's 50 day moving average is $29.37 and its 200 day moving average is $28.17. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The stock has a market cap of $7.22 billion, a P/E ratio of -48.88 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same quarter last year, the business earned $0.17 earnings per share. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. Analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 6,236 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $27.86, for a total value of $173,734.96. Following the completion of the sale, the insider owned 304,270 shares of the company's stock, valued at $8,476,962.20. This trade represents a 2.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 29,277 shares of the business's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total value of $876,846.15. Following the transaction, the chief financial officer owned 236,527 shares in the company, valued at approximately $7,083,983.65. This trade represents a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 128,684 shares of company stock worth $3,731,869 over the last quarter. Company insiders own 11.76% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc boosted its stake in Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after purchasing an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after purchasing an additional 319 shares during the last quarter. Compass Financial Management LLC acquired a new position in Hims & Hers Health during the 2nd quarter valued at approximately $50,000. Eurizon Capital SGR S.p.A. acquired a new position in Hims & Hers Health during the 4th quarter valued at approximately $59,000. Finally, Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Hims & Hers Health in the fourth quarter worth $80,000. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.